ADC selectively kills tumor cells and reduces systemic toxicity by partially binding to tumor cell surface antigens (such as HER-2, CD79b, etc) through antibodies, internalizing them into cells, and releasing toxins (such as microtubule inhibitor: monomethyl auristatin E (MMAE) or topoisomerase inhibitor SN-38).6 Here, ERBB2 is linked to neoplasm.